Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor
- PMID: 18062779
- DOI: 10.1111/j.1600-0854.2007.00682.x
Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor
Abstract
Immune responses are modulated by activating and inhibitory receptors that traffic to and from the cell surface. Ligands that bind to inhibitory receptors induce phosphorylation of immunoreceptor tyrosine-based inhibitory motifs (ITIMs) in their cytoplasmic tails, followed by recruitment of inhibitory signaling molecules. Mechanisms that control the surface levels of inhibitory receptors are largely unexplored. Here, we show, using CD33/sialic acid-binding immunoglobulin-like lectin (Siglec)-3 as a paradigm, that ITIMs can bind to the ubiquitin ligase Cbl and that ITIMs are ubiquitylated following Src family kinase-mediated tyrosine phosphorylation. Ubiquitylation is a known signal for endocytosis. Accordingly, cells expressing CD33 mutants that cannot become ubiquitylated show significantly increased cell surface expression of CD33 and have impaired CD33 internalization, whereas in-frame fusion of ubiquitin to CD33 reverses this phenotype. Our results identify a novel function of ITIMs and demonstrate that phosphorylation-dependent ubiquitylation regulates cell surface expression and internalization, and thus possibly function, of CD33/Siglec-3, suggesting an important role of ubiquitin in endocytosis of ITIM-bearing inhibitory immunoreceptors.
Similar articles
-
ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2.J Leukoc Biol. 2008 Jan;83(1):200-11. doi: 10.1189/jlb.0607388. Epub 2007 Oct 18. J Leukoc Biol. 2008. PMID: 17947393
-
CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover.Blood. 2007 Feb 1;109(3):1061-8. doi: 10.1182/blood-2006-05-023556. Epub 2006 Sep 28. Blood. 2007. PMID: 17008544
-
The sialoadhesin CD33 is a myeloid-specific inhibitory receptor.Eur J Immunol. 1999 Nov;29(11):3440-9. doi: 10.1002/(SICI)1521-4141(199911)29:11<3440::AID-IMMU3440>3.0.CO;2-C. Eur J Immunol. 1999. PMID: 10556798
-
New I-type lectins of the CD 33-related siglec subgroup identified through genomics.Biochem Soc Symp. 2002;(69):83-94. doi: 10.1042/bss0690083. Biochem Soc Symp. 2002. PMID: 12655776 Review.
-
Ubiquitin and endocytic internalization in yeast and animal cells.Biochim Biophys Acta. 2004 Nov 29;1695(1-3):89-111. doi: 10.1016/j.bbamcr.2004.09.024. Biochim Biophys Acta. 2004. PMID: 15571811 Review.
Cited by
-
Ubiquitination of human leukocyte antigen (HLA)-DM by different membrane-associated RING-CH (MARCH) protein family E3 ligases targets different endocytic pathways.J Biol Chem. 2012 Mar 2;287(10):7256-64. doi: 10.1074/jbc.M111.305961. Epub 2012 Jan 13. J Biol Chem. 2012. PMID: 22247549 Free PMC article.
-
Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.Front Immunol. 2018 Dec 7;9:2807. doi: 10.3389/fimmu.2018.02807. eCollection 2018. Front Immunol. 2018. PMID: 30581432 Free PMC article. Review.
-
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.Neuron. 2013 May 22;78(4):631-43. doi: 10.1016/j.neuron.2013.04.014. Epub 2013 Apr 25. Neuron. 2013. PMID: 23623698 Free PMC article.
-
Control of Innate Immunity by Sialic Acids in the Nervous Tissue.Int J Mol Sci. 2020 Jul 31;21(15):5494. doi: 10.3390/ijms21155494. Int J Mol Sci. 2020. PMID: 32752058 Free PMC article. Review.
-
Siglecs as targets for therapy in immune-cell-mediated disease.Trends Pharmacol Sci. 2009 May;30(5):240-8. doi: 10.1016/j.tips.2009.02.005. Epub 2009 Apr 7. Trends Pharmacol Sci. 2009. PMID: 19359050 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous